CoChat

Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Background: HIF-1 deficiency has marked effects on tumour glycolysis and growth. We therefore investigated the consequences of HIF-1 deficiency in mice, using the well established Hepa-1 wild-type (WT) and HIF-1β-deficient (c4) model. These mechanisms could be clinically relevant, since HIF-1 is now a therapeutic target. Methods: Hepa-1 WT and c4 tumours grown in vivo were analysed by 18 FDG-PET and 19 FDG Magnetic Resonance Spectroscopy for glucose uptake; by HPLC for adenine nucleotides; by immunohistochemistry for GLUTs; by immunoblotting and by DIGE followed by tandem mass spectrometry for protein expression; and by classical enzymatic methods for enzyme activity. Results: HIF-1β deficient Hepa-1 c4 tumours grew significantly more slowly than WT tumours, and (as expected) showed significantly lower expression of many glycolytic enzymes. However, HIF-1β deficiency caused no significant change in the rate of glucose uptake in c4 tumours compared to WT when assessed in vivo by measuring fluoro-deoxyglucose (FDG) uptake. Immunohistochemistry demonstrated less GLUT-1 in c4 tumours, whereas GLUT-2 (liver type) was similar to WT. Factors that might upregulate glucose uptake independently of HIF-1 (phospho-Akt, c-Myc) were shown to have either lower or similar expression in c4 compared to WT tumours. However the AMP/ATP ratio was 4.5 fold higher (p < 0.01) in c4 tumours, and phosphofructokinase-1 (PFK-1) activity, measured at prevailing cellular ATP and AMP concentrations, was up to two-fold higher in homogenates of the deficient c4 cells and tumours compared to WT (p < 0.001), suggesting that allosteric PFK activation could explain their normal level of glycolysis. Phospho AMP-Kinase was also higher in the c4 tumours. Conclusions: Despite their defective HIF-1 and consequent down-regulation of glycolytic enzyme expression, Hepa-1 c4 tumours maintain glucose uptake and glycolysis because the resulting low [ATP] high [AMP] allosterically activate PFK-1. This mechanism of resistance would keep glycolysis functioning and also result in activation of AMP-Kinase and growth inhibition; it may have major implications for the therapeutic activity of HIF inhibitors in vivo. Interestingly, this control mechanism does not involve transcriptional control or proteomics, but rather the classical activation and inhibition mechanisms of glycolytic enzymes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2407-11-198

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Growth and FDG uptake characteristics of Hepa-1 c4 and WT tumours. A. Comparison of growth rate from Hepa-1 c4 and WT tumours. The Hepa-1 c4 (●) tumours had a slower growth rate compared with the WT (□) tumours and growth rates were significantly different at days 17, 21 and 24 (p < 0.05) (n = 10) but not at 28 days (p > 0.1). B. The uptake of FDG in Hepa-1 c4 (●) and WT (□) tumours measured by 18FDG -PET. Data were expressed as standardised uptake (SUV) (n = 4-6). For details see Methods. C. The uptake of 19FDG measured by 19F MRS in Hepa-1 c4 (●) and WT (□) tumours.
Figure 1 Growth and FDG uptake characteristics of Hepa-1 c4 and WT tumours. A. Comparison of growth rate from Hepa-1 c4 and WT tumours. The Hepa-1 c4 (●) tumours had a slower growth rate compared with the WT (□) tumours and growth rates were significantly different at days 17, 21 and 24 (p < 0.05) (n = 10) but not at 28 days (p > 0.1). B. The uptake of FDG in Hepa-1 c4 (●) and WT (□) tumours measured by 18FDG -PET. Data were expressed as standardised uptake (SUV) (n = 4-6). For details see Methods. C. The uptake of 19FDG measured by 19F MRS in Hepa-1 c4 (●) and WT (□) tumours.CC BY · PubMed Central
Figure 2 Immunohistochemistry staining for GLUT 1 and 2 in Hepa-1 c4 and WT tumours. Panels show GLUT-1 staining for c4 (A) and WT (B), negative staining for GLUT-1 in c4 (C) and WT (D), GLUT-2 staining for c4 (E) and WT (F), negative staining for GLUT-2 in c4 (G) and WT (H). The arrows indicate significant areas of staining.
Figure 2 Immunohistochemistry staining for GLUT 1 and 2 in Hepa-1 c4 and WT tumours. Panels show GLUT-1 staining for c4 (A) and WT (B), negative staining for GLUT-1 in c4 (C) and WT (D), GLUT-2 staining for c4 (E) and WT (F), negative staining for GLUT-2 in c4 (G) and WT (H). The arrows indicate significant areas of staining.CC BY · PubMed Central
Figure 3 Protein expression in Hepa-1 c4 and Hepa-1 WT tumours. A. Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for Akt and its phosphorylated form. For details see Methods.B. Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for c-Myc and its phosphorylated form. C. Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for LDH and PK. For details see Methods.D. Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for PDK1 and PDK2.E. Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for phospho-AMPK.
Figure 3 Protein expression in Hepa-1 c4 and Hepa-1 WT tumours. A. Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for Akt and its phosphorylated form. For details see Methods.B. Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for c-Myc and its phosphorylated form. C. Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for LDH and PK. For details see Methods.D. Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for PDK1 and PDK2.E. Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for phospho-AMPK.CC BY · PubMed Central
Figure 4 PFK activity measured in c4 and WT cells and tumours under optimal conditions and those prevailing in vivo. PFK activity (nmol/mg protein/min) measured either under optimal conditions (1 mM ATP, 2 mM AMP) or under the conditions prevailing in vivo (0.7 mM ATP and 0.25 mM AMP for c4; 1 mM ATP and 0.04 mM AMP for WT). No significant difference in PFK activity was seen when measured under optimal conditions comparing WT and c4 tumours or cells (p > 0.1). However, under conditions prevailing in vivo, PFK activity was significantly higher in c4 than in WT cells or tumours (p < 0.005).
Figure 4 PFK activity measured in c4 and WT cells and tumours under optimal conditions and those prevailing in vivo. PFK activity (nmol/mg protein/min) measured either under optimal conditions (1 mM ATP, 2 mM AMP) or under the conditions prevailing in vivo (0.7 mM ATP and 0.25 mM AMP for c4; 1 mM ATP and 0.04 mM AMP for WT). No significant difference in PFK activity was seen when measured under optimal conditions comparing WT and c4 tumours or cells (p > 0.1). However, under conditions prevailing in vivo, PFK activity was significantly higher in c4 than in WT cells or tumours (p < 0.005).CC BY · PubMed Central
Figure 5 Pathways concerned with the regulation of glycolysis and the effects of HIF-1 deficiency in Hepa-1 tumours. In the wild-type tumours (WT), [ATP] would tend to inhibit PFK activity. However in HIF-1 deficiency (c4), enzymes in the glycolytic pathway are down-regulated to 42-74% of the WT protein expression and the resulting decrease in [ATP] causes an increase in [AMP] (due to the adenylate kinase equilibrium). AMP acts as an allosteric activator of PFK, and the ATP/AMP ratio in c4 tumours doubles the PFK catalytic activity (see Figure 4), allowing glycolytic flux through the pathway (glucose to lactate) to be maintained at WT levels.
Figure 5 Pathways concerned with the regulation of glycolysis and the effects of HIF-1 deficiency in Hepa-1 tumours. In the wild-type tumours (WT), [ATP] would tend to inhibit PFK activity. However in HIF-1 deficiency (c4), enzymes in the glycolytic pathway are down-regulated to 42-74% of the WT protein expression and the resulting decrease in [ATP] causes an increase in [AMP] (due to the adenylate kinase equilibrium). AMP acts as an allosteric activator of PFK, and the ATP/AMP ratio in c4 tumours doubles the PFK catalytic activity (see Figure 4), allowing glycolytic flux through the pathway (glucose to lactate) to be maintained at WT levels.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 1

  1. Berg JM, Tymoczko JL, Stryer L: Biochemistry. 2007, WH Freeman, New York, 763-6

Cited by

See all 31

Metadata

Authors
Golinska, M., Troy, H., Chung, Y.-L., McSheehy, P. M., Mayr, M., Yin, X., Ly, L., Williams, K. J., Airley, R. E., Harris, A. L., Latigo, J., Perumal, M., Aboagye, E. O., Perrett, D., Stubbs, M., & Griffiths, J. R.
Affiliations
  • Cancer Research UK Cambridge Center (GB)
  • St George's, University of London (GB)
  • Institute of Cancer Research (GB)
  • Novartis (Switzerland) (CH)
  • University of Manchester (GB)
  • University of Huddersfield (GB)
  • John Radcliffe Hospital (GB)
  • Hammersmith Hospital (GB)
  • Queen Mary University of London (GB)
Corresponding author
  • Stubbs, Marion
  • Griffiths, John R
Venue
BMC Cancer
Published
2011-05-25
Volume
11
Issue
1
Pages
198-198
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2170955124
Cited by
29
References
36
Citations by year
2026: 4 · 2024: 2 · 2023: 1 · 2022: 5 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2015: 3 · 2014: 3 · 2013: 5
FWCI
0.87
Type
journal article
Language
en
Open access
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • University of Huddersfield Repository (University of Huddersfield) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • Cancer Research UK (10337, 11562)
  • British Heart Foundation (FS/08/002/24537)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
Keywords
ARNT, hepatocellular carcinoma, AMP/ATP ratio, phosphofructokinase-1, glucose uptake, GLUT1, AMPK, c-Myc, Akt, tumor growth
MeSH terms
Adaptation, Biological, Adenosine Monophosphate, Adenosine Triphosphate, Adenylate Kinase, Allosteric Regulation, Animals, Enzyme Activation, Glucose, Glycolysis, Carcinoma, Hepatocellular, Liver Neoplasms, Mice, Nude, Up-Regulation, Phosphofructokinases, Proteomics, Cell Proliferation, Glucose Transport Proteins, Facilitative, Mice, Hypoxia-Inducible Factor 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas. https://app.cochat.ai/papers/10.1186/1471-2407-11-198
The paper
Golinska, M., Troy, H., Chung, Y.-L., McSheehy, P. M., Mayr, M., Yin, X., Ly, L., Williams, K. J., Airley, R. E., Harris, A. L., Latigo, J., Perumal, M., Aboagye, E. O., Perrett, D., Stubbs, M., & Griffiths, J. R. (2011). Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas. BMC Cancer. https://doi.org/10.1186/1471-2407-11-198

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.